Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MGTA Magenta Therapeutics (MGTA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Magenta Therapeutics Stock (NASDAQ:MGTA) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Magenta Therapeutics alerts:Sign Up Key Stats Today's Range$0.68▼$0.7650-Day Range$0.36▼$0.7652-Week Range$0.32▼$2.07Volume376,000 shsAverage Volume848,835 shsMarket Capitalization$42.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTA Stock News HeadlinesMagenta Living and Seddon team up to help apprentices using Widnes-based developmentOctober 11, 2024 | msn.comMagenta Living and Bolton-based Seddon Housing Partnerships team up to help apprenticesOctober 9, 2024 | msn.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Magenta sharing gas safety advice at pop-ups this weekSeptember 11, 2024 | msn.comDelhi Metro Phase-IV: Safety nod in, Magenta Line extension may open next monthAugust 30, 2024 | msn.comMagenta Buyer LLC Raises $400 Million of New CapitalAugust 15, 2024 | finance.yahoo.comMagenta secures $105m to trial world’s smallest heart pumpJuly 25, 2024 | finance.yahoo.comMagenta Medical Closes $105M Financing Led by Novo HoldingsJuly 23, 2024 | finance.yahoo.comSee More Headlines MGTA Stock Analysis - Frequently Asked Questions How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02. When did Magenta Therapeutics' stock split? Magenta Therapeutics shares split on the morning of Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly created shares were distributed to shareholders after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. When did Magenta Therapeutics IPO? Magenta Therapeutics (MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Magenta Therapeutics investors own include TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), NIO (NIO), Outlook Therapeutics (OTLK), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). Company Calendar Last Earnings11/04/2021Today11/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 201-2700FaxN/AEmployees67Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.88% Return on Assets-57.27% Debt Debt-to-Equity RatioN/A Current Ratio19.49 Quick Ratio19.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book0.57Miscellaneous Outstanding Shares60,665,000Free Float51,456,000Market Cap$42.44 million OptionableNot Optionable Beta2.12 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MGTA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Magenta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.